Oxaprozin
Spezifikationen
21256-18-8CAS-Nummer
244-296-1EG-Nummer
3-(4,5-diphenyl-1,3-oxazol-2-yl)propanoic acidIUPAC-Name
C18H15NO3Chemische Formel
293.3 g/molMolekulargewicht
oxaprozin; 21256-18-8; Daypro; 3-(4,5-Diphenyloxazol-2-yl)propanoic acid; Alvo; Oxaprozine; Oxaprozinum; Deflam; Oxaprozina; 4,5-Diphenyl-2-oxazolepropanoic acid; 4,5-Diphenyl-2-oxazolepropionic acid; WY-21743; WY-21,743; 2-Oxazolepropanoic acid, 4,5-diphenyl-; Duraprox; DTXSID1045118; WY 21743; COXANTO; NSC310839; NSC-310839; MHJ80W9LRB; beta-(4,5-Diphenyloxazol-2-yl)propionic acid; 3-(diphenyl-1,3-oxazol-2-yl)propanoic acid; CHEBI:7822; DTXCID9025118; Apo Oxaprozin; Rhoxal oxaprozin; Oxaprozin (USAN:USP:INN:BAN:JAN); Oxaprozin [USAN:USP:INN:BAN:JAN]; 4,5 Diphenyl 2 oxazolepropionic Acid; Wy 21,743; RefChem:56403; M01AE12; 244-296-1; 3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoic acid; Oxaprozine [INN-French]; Oxaprozinum [INN-Latin]; Oxaprozina [INN-Spanish]; MFCD00215977; Oxaprozinum;Wy21743; 3-(4,5-Diphenyl-2-oxazolyl)propenoic acid; NSC 310839; CHEMBL1071; Voir; 2-OXAZOLEPROPIONIC ACID, 4,5-DIPHENYL-; .beta.-(4,5-Diphenyloxazol-2-yl)propionic acid; Danoprox; Dayrun; CAS-21256-18-8; Actirin; Xopane; SMR000058286; Daypro (TN); SR-01000076053; oxaprosin; Durapro; Duraprost; Oxaprozi; Oxapro; Walix; Oxaprozin, solid; EINECS 244-296-1; NCI310839; Oxaprozin (Standard); 4, 5-Diphenyl-2-oxazolepropionic acid; BRN 1083168; OXAPROZIN [INN]; OXAPROZIN [JAN]; OXAPROZIN [MI]; OXAPROZIN [HSDB]; OXAPROZIN [USAN]; 3-(4,5-Diphenyl-2-oxazolyl)propionic acid; Maybridge1_008800; Prestwick0_001060; Prestwick1_001060; Prestwick2_001060; Prestwick3_001060; Spectrum2_001696; Spectrum3_001078; Spectrum4_001231; UNII-MHJ80W9LRB; Lopac-O-9637; OXAPROZIN [VANDF]; OXAPROZIN [MART.]; O 9637; OXAPROZIN [USP-RS]; OXAPROZIN [WHO-DD]; SCHEMBL3286; NCIStruc1_000799; NCIStruc2_000787; BIDD:PXR0149; Lopac0_000944; Oprea1_509470; BSPBio_001020; BSPBio_002696; KBioGR_001722; MLS000759535; MLS001424072; BIDD:GT0438; SPECTRUM1505267; Oxaprozin - Bio-X trade mark; SPBio_001652; SPBio_002940; Oxaprozin (JP18/USP/INN); BPBio1_001122; GTPL7252; orb1310364; orb3025231; OXAPROZIN [ORANGE BOOK]; HMS566H22; HSDB 7586; HY-B0808R; KBio3_001916; MSK7199; OXAPROZIN [USP MONOGRAPH]; GLXC-23892; HMS1571C22; HMS1922P17; HMS2051L15; HMS2093O08; HMS2098C22; HMS3262N10; HMS3393L15; HMS3652H17; HMS3715C22; HMS3885L11; HMS5082D16; Pharmakon1600-01505267; Wy21743; HY-B0808; Tox21_110059; Tox21_500944; 2-Oxazolepropanoic acid,5-diphenyl-; 2-Oxazolepropionic acid,5-diphenyl-; BDBM50002861; CCG-36508; EBC-04209; MSK7199-100M; NCGC00014711; NSC758949; s4230; SBB053166; 4,5-diphenyloxazole-2-propanoic acid; AKOS000206807; Tox21_110059_1; CS-7975; DB00991; FO26614; KS-5196; LP00944; NC00214; NSC-758949; SDCCGSBI-0050918.P004; NCGC00014711-01; NCGC00014711-02; NCGC00014711-03; NCGC00014711-04; NCGC00014711-05; NCGC00014711-06; NCGC00014711-07; NCGC00014711-08; NCGC00014711-09; NCGC00014711-10; NCGC00014711-11; NCGC00014711-14; NCGC00014711-15; NCGC00094249-01; NCGC00094249-02; NCGC00094249-03; NCGC00094249-04; NCGC00094249-05; NCGC00094249-06; NCGC00094249-07; NCGC00261629-01; Oxaprozin 100 microg/mL in Acetonitrile; AC-26512; BO164184; NCI60_002681; SY050819; Oxaprozin Solution in Methanol, 100ug/mL; SBI-0050918.P002; 3-(4,5-Diphenyl-2-oxazolyl)propanoic acid; 3-(4,5-Diphenyloxazol-2-yl)propionic acid; AB00514024; EU-0100944; NS00008254; O0377; ST50949623; SW197319-4; 3-(4, 5-Diphenyl-2-oxazolyl)propenoic acid; EN300-25629; 3-(4,5-Diphenyl-oxazol-2-yl)-propionic acid; C07356; D00463; AB00514024_08; AB00514024_09; F066202; Q1749609; SR-01000076053-1; SR-01000076053-3; SR-01000076053-7; SR-01000076053-9; 3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoic acid #; BRD-K25394294-001-05-7; BRD-K25394294-001-08-1; BRD-K25394294-001-13-1; BRD-K25394294-001-14-9; Z212055564; Oxaprozin, United States Pharmacopeia (USP) Reference Standard; BJ6Synonyme
